In stressful times, are we making our pets anxious? Causes and cures for pet anxiety
The answer isn't simple, says Frankie Jackson, a veterinary nurse and animal behavior consultant, and the owner of Canine Counseling in Smyrna, Georgia. She said she's seen an increase in anxiety among her animal and human clients, but that it's hard to unwind the cause and effect.
'Dogs are incredibly responsive to our expressions, our body language and our scent,' she says. 'There is a feedback loop — the owners are nervous; the dog gets nervous. Our cortisol levels rise and fall in tandem.'
Dr. Becky Peters, a veterinarian and owner of Bath Veterinary Hospital in Bath, New York, has also noticed a link between the anxiety of pets and their owners, particularly in the exam room.
'If owners try to over comfort them — lots of 'you're OK!'' in anxious voices, the animals do get more anxious. If we stay calm and quiet, they do too,' Peters says.
Peters attributes much of the rise in pet anxiety to the social upheaval of the COVID years. Many animals who were acquired during the pandemic had limited opportunities to socialize with other people and pets during their peak developmental stages. After COVID, pets who were used to having their family at home experienced separation anxiety as their owners returned to work and school.
'A lot of pet anxiety comes from changes to their households,' Peters says. 'It can also occur from a lack of routine and structure and not enough physical activity.'
Other components that could contribute to our pets' anxiety include unmet needs, past trauma and insufficient open spaces.
'We are asking our dogs to live in a world that isn't made for them,' she says.
Try to get at the cause of your pet's anxietyLow-level stress responses in dogs, such as eating less and excessive self-grooming, are forms of communication that precede lunging and barking, Jackson says. Trying to solve reactive behaviors through obedience training without addressing the root cause can make dogs' anxiety worse.
'It's important to understand what the dogs are saying and why they're behaving the way they are. Manners and life skills are important, but it won't create happy dogs,' Jackson says.
Anxiety in cats can be harder to spot, according to Jackson, because they're hard-wired to hide it. While dogs seek out their support people, cats don't feel safe expressing their vulnerability. Urinating in the house, scratching, hiding under the bed and overgrooming can be signs that your kitty is anxious.
First, see a vet
If your animal companion is suddenly acting out or on a licking binge, Jackson advises seeing a veterinarian to rule out a medical cause, such as pain or allergies.
Veterinarians can also prescribe anti-anxiety medication and complementary treatments to promote sleep and relaxation. Peters recommends supplements for her canine clients including probiotics and the amino acids l-theanine and tryptophan (yes, the turkey coma one).
For cats, she suggests using a product like Feliway that diffuses calming pheromones into the air.
Learn about the breed
A dog's breed might also play a part in developing anxiety. Peters says that while every dog is different, the more active herding and working breeds like shepherds and border collies can become anxious and destructive without an outlet for their energy.
'Herding breeds need space to run and jobs to do,' she says.
When Tacoma, Washington, resident Shelani Vanniasinkam got her Australian shepherd puppy, Roo, she didn't know about the breed's reputation for anxiety. Her previous dog had been an easygoing husky who enjoyed pats from strangers and visits to the dog park. She quickly realized Roo was not that type of dog.
'He had a lot more needs than we anticipated,' Vanniasinkam says. 'We couldn't leave him alone for more than 30 minutes.'
Vanniasinkam and her husband, Jesus Celaya, reached out to a local pet behavioralist, but it became clear that Roo's anxiety was so acute he needed medication before he could start behavior training.
Should you consider meds for an anxious pet?Medication can be important in behavioral treatment, but it shouldn't be the only approach, says Peters. She usually suggests that her clients try training and routine modification first, unless their pet is causing harm to themselves or others.
'If I'm going to use meds, it's part of a greater process,' Peters says.
Roo's veterinarian put him on Fluoxetine, or 'doggie Prozac,' an antidepressant commonly given to anxious pets. He also prescribed Trazodone, another antidepressant, for particularly stressful events, such as trips to the vet or a night of fireworks.
After starting his medication, Roo received eight months of behavior training, during which Vanniasinkam and her husband not only changed their own approach to dog parenting but also set boundaries with friends and family. They limited Roo's interaction with other dogs, asked people to stop using their doorbell and requested that others ignore Roo when he barks.
Now, when they want to take Roo for off-leash play, they book time at a local Sniffspot, which Vanniasinkam describes as 'an Airbnb for anxious and reactive dogs.' The company, which launched in 2016, allows homeowners to rent out their yards or property by the hour for solo, off-leash play or doggie playdates.
'It's sad when you can't take your dog to a dog park,' Vanniasinkam says. 'So, this option is really nice.'
She says that while it was initially difficult to navigate Roo's anxiety, he is loving, family-oriented and worth the effort.
'It's hard having an anxious dog, but you can figure it out,' she says. 'It's just important to understand your dog, so you're set up for success.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
US: RFK Jr. risking 'nation's health' with misinformation
Over 750 US Department of Health and Human Services staff on Wednesday called on Secretary Robert F. Kennedy Jr. to ensure health workers' safety. A signed open letter said health staff were being put at risk by misleading claims about vaccines and infectious diseases and came in the wake of this month's deadly shooting at Centers for Disease Control and Prevention (CDC) buildings in Atlanta. What was said in the letter? The open letter said Kennedy "is complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information," and implored the health chief to change his stance. "The deliberate destruction of trust in America's public health workforce puts lives at risk. We urge you to act in the best interest of the American people — your friends, your families, and yourselves," the letter said. Wednesday's letter was signed by former CDC leaders such as Anne Schuchat, a former principal deputy director, although many who signed did so anonymously for fear of retaliation. CDC gun attack 'not random' On August 8, a man fired nearly 200 rounds at six CDC buildings, killing a police officer in the process before taking his own life. Investigators said that notes found at the gunman's residence suggested discontent with the COVID-19 vaccine, blaming it for making him sick. Those who signed the open letter said that the attack "was not random," and pointed to "growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization — and now, violence." Kennedy has been a long-time vaccine skeptic and notably removed all 17 members of the CDC's vaccine advisory panel last June. He announced earlier this month that research funding for mRNA vaccines would be slashed. Kennedy argued that the vaccines had failed to protect effectively against infections like COVID and flu. Edited by: John Silk


Forbes
4 minutes ago
- Forbes
Key Takeaways For CIOs From Epic UGM 2025
Epic's latest UGM conference followed the industry trend: another major tech event dominated by AI agent announcements. CIOs are focusing on strategies that improve patient care, streamline operations, and strengthen data security in a digital-first environment. These three themes from the UGM conference not only stand out but also carry significant strategic implications for the future of healthcare IT. Ambient Solution Is a Commodity Ambient documentation has crossed into commodity territory. Epic is embedding an ambient solution through its Microsoft partnership as part of the EMR, cementing that reality, but questions remain. How will pricing shake out? And for organizations already piloting Microsoft Dragon Copilot, will physician-level customizations transfer cleanly, or will workflows need rebuilding? CIOs must factor that transition risk into every decision. Health systems that are investors with early-stage, ambient, standalone vendors won't jump ship quickly. Many will wait for a favorable exit because in venture capital and private equity, an exit is always a possibility. The real issue is timing and whether it aligns with CIOs' operational roadmaps. As ambient becomes standard, point-solution vendors face a make-or-break moment. They must layer on new capabilities, go deeper into the EHR, or pivot to adjacent problems. CIOs need to identify which partners have staying power once the ambient advantage disappears. Cosmos Cosmos is becoming Epic's crown jewel. With de-identified data from more than 300 million patients and 16 billion encounters, Epic sits on a prediction engine at unmatched scale. Its partnership with Yale and Microsoft Research produced CoMET, a model trained on 151 billion events that learns by forecasting the next step in a patient's health journey. Epic stress-tested the CoMET model across 78 real-world tasks, including diagnosis prediction, disease prognosis, and healthcare operations. The model performed just as well as or better than specialized predictive models without requiring much fine-tuning. CoMET will deliver tools like Median Length-of-Stay for Discharge Planning, pushing predictive AI straight into operations. As the dataset grows, the models get stronger, and stronger models deliver sharper insights. CIOs and healthcare operators must act now to embed these predictions into their operational workflow. Universal Patient ID Epic hasn't announced plans for a universal patient ID, but the pieces are in place and the path is clear. Patients juggling multiple MyChart accounts or moving across systems want one login. Epic announced MyChart Central, a feature that will allow patients to connect their records from different providers using a single Epic-issued ID. Through a partnership with CLEAR, patients can now verify their identity securely with biometrics. This integration streamlines account creation and recovery in both MyChart and EpicCare Link, cutting administrative workload while strengthening security across the enterprise. As more standalone solution capabilities fold into Epic's EMR platform, a larger question emerges: Will market consolidation leave enough competition to drive real innovation? Healthcare leaders must balance the appeal of a comprehensive solution with the industry's need for diverse and inventive players.


Indianapolis Star
7 minutes ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.